NVIDIA GTC 2026 Interviews: AI Is Only Becoming More Important
Summary
Amit explores the transition from reasoning-based AI models to autonomous agents through interviews with NVIDIA leadership at the GTC event. Amit argues that we are entering the 'moment of agents,' where software like OpenClaw and NVIDIA's NemoClaw provides unbounded autonomy to perform tasks ranging from coding to managing household systems. Amit emphasizes that the future of the software industry will shift from selling individual seats to offering 'agents-as-a-service,' where AI agents act as super-engineers and knowledge workers rather than simple replacements for human labor.
In the realm of healthcare, Amit highlights NVIDIA's role as an accelerated computing platform rather than just a chip manufacturer. Amit states that AI is being used to revolutionize three key areas: digital devices (like surgical robotics), digital biology (drug discovery), and digital health (physician empowerment). Amit points out that the traditional 10-year, $2 billion drug discovery process is being disrupted by 'in-silico' exchange loops that allow for low-latency scientific discovery. Amit also notes a trend toward 'democratized healthcare,' where consumers use AI models to interpret genomic and blood data to take proactive control of their health.
Mentioned Stocks
Reasoning: Amit views NVIDIA as the foundational platform for both the next generation of autonomous software agents and the digital transformation of healthcare. Amit highlights their open-source approach to models and data, alongside high-profile partnerships like the $1 billion lab with Eli Lilly, as reasons for their continued market dominance.
Reasoning: Amit identifies ServiceNow as a leader in applying agentic AI to real-world business problems, specifically noting that 90% of their L1 support tickets are now automated. Amit argues this proves the productivity thesis of AI in the enterprise sector.
Reasoning: Amit highlights the $1 billion long-term partnership between Eli Lilly and NVIDIA as a major catalyst for the stock. Amit notes that their commitment to building 'in-silico' discovery loops will drastically reduce the time and cost associated with drug development.